Risks of Gaucher's treatment [4]

Lancet

Volumn 356, Issue 9238, 2000, Pages 1353-1354

  Barranger, John A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MIGLUSTAT; N BUTYLEDEOXYNOJIRIMICIN; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; DISEASE SEVERITY; DRUG POTENCY; DRUG SAFETY; GAUCHER DISEASE; HUMAN; LETTER; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0034649051     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)74261-6     Document Type: Letter

References (3)

1. Treatment of Gaucher's disease with OGT 918
2. Novel oral treatment to Gaucher's disease with N-butyledeoxynojirimicin (OGT 918) to decrease substrate biosynthesis
3. N-butyledeoxynojirimicin: A more selective inhibitor of glycosphingolipid biosynthesis than N-butyledeoxynojirimicin, in vitro and in vivo